Epigenomics (ECX)

Business description

Initial data from the PRESEPT study on the bowel cancer test, Sept9, were released on 15 January. One laboratory had a lower detection rate than the others but it seems likely that Sept9 will detect 50-62.5% of colon cancer patients including many patients with curable early stage disease. An audit of the laboratories is ongoing and retesting of samples may occur. Final data should be released by late March. However, 96.5% of positive tests will prove negative on colonoscopy examination.

Termination of coverage

Update | Pharmaceutical & healthcare | 13/04/2017

Edison Investment Research is terminating coverage on Epigenomics (ECX). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Edison's research is freely available. We will never ask for your credit card details and you do not need to register. By downloading this research you are agreeing to our terms and conditions, which you can read in full here.

Company news

Epigenomics

Thu, 27 Apr 2017 12:18:19 GMT

Epigenomics

Wed, 26 Apr 2017 02:02:47 GMT

Epigenomics

Wed, 13 Apr 2016 18:11:15 GMT

Epigenomics

Wed, 16 Jan 2013 13:42:20 GMT

Epigenomics

Fri, 19 May 2017 18:56:15 GMT